Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Revolutionary advancements in blood cancer treatment, from targeted therapy to gene editing, promise more effective and ...

Asciminib shows superior tolerability over nilotinib in newly diagnosed CML-CP patients, reducing treatment discontinuation ...

In interim analysis of phase 2 ASC2ESCALATE trial, patients with chronic-phase chronic myeloid leukemia who fail to respond ...

Treating blast phase CML. Blast phase CML is where your CML transforms to an acute leukaemia. The drugs you have for the blast phase CML depends on the type of leukaemia your CML develops into. CML ...

Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which ...

Adolescent and young adult (AYA) patients with hematological diseases have unique needs that require a multidisciplinary ...

Survival (prognosis) for chronic myeloid leukaemia (CML) depends on several factors such as age. No one can tell you exactly how long you will live. CML is usually a slowly developing condition and ...

Background: ASC, the first BCR::ABL1 inhibitor to Specifically Target the ABL Myristoyl Pocket, recently received FDA Accelerated Approval for newly diagnosed CML-CP based on major molecular response ...

Basically, Transcutaneous Electrical Nerve Stimulation (TENS) therapy uses low-voltage electrical impulses to stimulate your ...

Help For Adults Facing Chronic Myeloid Leukemia. by AFL. Mon, June 2nd 2025 at 10:55 AM. ... but finding a treatment where side effects may be manageable for patients and that keeps cancer cells ...